Patents by Inventor Andreas HALL
Andreas HALL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240071593Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.Type: ApplicationFiled: October 24, 2023Publication date: February 29, 2024Inventors: Anna Leigh DAVIS, Scott M. BELLIVEAU, Naresh C. BHAVARAJU, Leif N. BOWMAN, Rita M. CASTILLO, Alexandra Elena CONSTANTIN, Rian W. DRAEGER, Laura J. DUNN, Gary Brian GABLE, Arturo GARCIA, Thomas HALL, Hari HAMPAPURAM, Christopher Robert HANNEMANN, Anna Claire HARLEY-TROCHIMCZYK, Nathaniel David HEINTZMAN, Andrea Jean JACKSON, Lauren Hruby JEPSON, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Aditya Sagar MANDAPAKA, Samuel Jere MARSH, Gary A. MORRIS, Subrai Girish PAI, Andrew Attila PAL, Nicholas POLYTARIDIS, Philip Thomas PUPA, Eli REIHMAN, Ashley Anne RINDFLEISCH, Sofie Wells SCHUNK, Peter C. SIMPSON, Daniel S. SMITH, Stephen J. VANSLYKE, Matthew T. VOGEL, Tomas C. WALKER, Benjamin Elrod WEST, Atiim Joseph WILEY
-
Patent number: 11505014Abstract: A system for determining a tire change status in a vehicle is provided. The system includes at least one processing device and a storage device. The at least one processing device may be arranged to: calculate a value of at least one reference parameter which may be used in indirect tire pressure monitoring; store the calculated value of said at least one reference parameter in the storage device; retrieve a previously stored value of said at least one reference parameter from the storage device; determine a similarity parameter based on a similarity between the calculated value and the previously stored value of said at least one reference parameter; and determine a tire change status, indicating whether or not the tires have been re-filled or replaced, by comparing said similarity parameter with a threshold.Type: GrantFiled: October 9, 2018Date of Patent: November 22, 2022Assignee: Nira Dynamics ABInventors: Rickard Karlsson, Peter Lindskog, Andreas Hall, Daniel Murdin, Robert Johansson, Martin Lilja
-
Publication number: 20200238770Abstract: A system for determining a tire change status in a vehicle is provided. The system includes at least one processing device and a storage device. The at least one processing device may be arranged to: calculate a value of at least one reference parameter which may be used in indirect tire pressure monitoring; store the calculated value of said at least one reference parameter in the storage device; retrieve a previously stored value of said at least one reference parameter from the storage device; determine a similarity parameter based on a similarity between the calculated value and the previously stored value of said at least one reference parameter; and determine a tire change status, indicating whether or not the tires have been re-filled or replaced, by comparing said similarity parameter with a threshold.Type: ApplicationFiled: October 9, 2018Publication date: July 30, 2020Applicant: Nira Dynamics ABInventors: Rickard KARLSSON, Peter LINDSKOG, Andreas HALL, Daniel MURDIN, Robert JOHANSSON, Martin LILJA
-
Publication number: 20180009429Abstract: The disclosed invention makes use of a wheel speed signal to detect a wheel anomaly such as a loose wheel or a wheel with zero pressure. The wheel speed signal is used as a basis to determine a first and a second detection signal. A further basis for determining the first and second detection signals are a first and second reference signal, respectively. The anomaly of e.g. a loose wheel is detected, according to the teaching of the invention if at least one of the detection signals exceeds a threshold. In particular, the disclosure relates to methods, systems and computer program products to achieve the mentioned objective.Type: ApplicationFiled: January 25, 2016Publication date: January 11, 2018Inventors: Andreas HALL, Robert JOHANSSON, Martin LILJA, Gustav LINDMARK, Peter LINDSKOG, Thomas SVANTESSON
-
Patent number: 8475798Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.Type: GrantFiled: June 16, 2006Date of Patent: July 2, 2013Assignees: Inhibitex, Inc., The Texas A&M University SystemInventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
-
Patent number: 7850974Abstract: A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: GrantFiled: October 8, 2009Date of Patent: December 14, 2010Assignees: The Texas A&M University System, Inhibitex, Inc., The UAB Research FoundationInventors: Magnus Hook, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Publication number: 20100183623Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.Type: ApplicationFiled: June 16, 2006Publication date: July 22, 2010Inventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
-
Publication number: 20100068220Abstract: A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: ApplicationFiled: October 8, 2009Publication date: March 18, 2010Inventors: Magnus HOOK, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Patent number: 7615616Abstract: A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®—like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: GrantFiled: September 15, 2003Date of Patent: November 10, 2009Assignees: The Texas A&M University System, Inhibitex, Inc., The UAB Research FoundationInventors: Magnus Hook, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Patent number: 7604949Abstract: The invention provides methods of screening for compounds that affect melanogenesis and the function of P protein in organisms, cells, or cell-free systems. The invention further relates to pharmacologic and cosmetic uses of methods of inhibiting melanogenesis, methods of activating melanogenesis, and compounds and pharmacologic compositions useful for the inhibition or activation of melanogenesis and, therefore, for lightening or darkening the pigmentation of cells and tissue, i.e., skin.Type: GrantFiled: April 20, 2006Date of Patent: October 20, 2009Assignee: New York UniversityInventors: Seth J. Orlow, Andrea Hall, Prashiela Manga
-
Patent number: 7364738Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: May 25, 2005Date of Patent: April 29, 2008Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 7115264Abstract: Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.Type: GrantFiled: November 5, 2002Date of Patent: October 3, 2006Assignee: INHIBITEXInventors: Joseph M. Patti, Pratisksha Patel, Andrea Hall, Paul Domanski, Peter Syribeys, Jeff T. Hutchins
-
Publication number: 20060188953Abstract: The invention provides methods of screening for compounds that affect melanogenesis and the function of P protein in organisms, cells, or cell-free systems. The invention further relates to pharmacologic and cosmetic uses of methods of inhibiting melanogenesis, methods of activating melanogenesis, and compounds and pharmacologic compositions useful for the inhibition or activation of melanogenesis and, therefore, for lightening or darkening the pigmentation of cells and tissue, i.e., skin.Type: ApplicationFiled: April 20, 2006Publication date: August 24, 2006Applicant: New York UniversityInventors: Seth Orlow, Andrea Hall, Prashiela Manga
-
Publication number: 20050287164Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: ApplicationFiled: May 25, 2005Publication date: December 29, 2005Inventors: Joseph Patti, Jeff Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 6979446Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: January 28, 2002Date of Patent: December 27, 2005Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Publication number: 20040175767Abstract: The invention provides methods of screening for compounds that affect melanogenesis and the function of P protein in organisms, cells, or cell-free systems. The invention further relates to pharmacologic and cosmetic uses of methods of inhibiting melanogenesis, methods of activating melanogenesis, and compounds and pharmacologic compositions useful for the inhibition or activation of melanogenesis and, therefore, for lightening or darkening the pigmentation of cells and tissue, i.e., skin.Type: ApplicationFiled: January 15, 2004Publication date: September 9, 2004Applicant: New York UniversityInventors: Seth J. Orlow, Andrea Hall, Prashiela Manga
-
Patent number: 6749840Abstract: The invention provides novel methods and pharmaceutical compositions designed to decrease melanin production by inhibiting fatty acid synthase in a melanocyte, thereby lightening skin pigmentation.Type: GrantFiled: May 2, 2002Date of Patent: June 15, 2004Assignee: New York UniversityInventors: Seth J. Orlow, Andrea Hall
-
Publication number: 20040101919Abstract: A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.Type: ApplicationFiled: September 15, 2003Publication date: May 27, 2004Inventors: Magnus Hook, Yi Xu, Jouko V. Sillanpaa, Narayana Sthanam, Karthe Ponnuraj, Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Maria G. Bowden
-
Publication number: 20040006209Abstract: Monoclonal and polyclonal antibodies are provided which recognize and bind to the SdrG protein of S. epidermidis, and more particularly to antibodies which recognize specific domains of the SdrG protein, namely the SdrG N1N2N3 protein (amino acids 50-597), the SdrG N2N3 protein (amino acids 273-597) and a truncated version of N2N3 identified as SdrG TR2 (amino acids 273-577).Type: ApplicationFiled: March 5, 2003Publication date: January 8, 2004Inventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Paul Domanski, Pratiksha Patel, Magnus Hook, Jeff Robbins, John Vernachio, Maria Bowden
-
Publication number: 20030153022Abstract: Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.Type: ApplicationFiled: November 5, 2002Publication date: August 14, 2003Inventors: Joseph M. Patti, Pratisksha Patel, Andrea Hall, Paul Domanski, Peter Syribeys, Jeff T. Hutchins